GBT
Price:
$68.49
Market Cap:
$0
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemogl...[Read more]
Industry
Biotechnology
IPO Date
2015-08-12
Stock Exchange
NASDAQ
Ticker
GBT
According to Global Blood Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -25100000.00. This represents a change of -101.21% compared to the average of 2.08B of the last 4 quarters.
The mean historical Enterprise Value of Global Blood Therapeutics, Inc. over the last ten years is 1.55B. The current -25100000.00 Enterprise Value has changed -261.78% with respect to the historical average. Over the past ten years (40 quarters), GBT's Enterprise Value was at its highest in in the December 2019 quarter at 4.57B. The Enterprise Value was at its lowest in in the March 2014 quarter at 0.
Average
1.55B
Median
1.47B
Minimum
265.54M
Maximum
4.41B
Discovering the peaks and valleys of Global Blood Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 278.34%
Maximum Annual Enterprise Value = 4.41B
Minimum Annual Increase = -50.94%
Minimum Annual Enterprise Value = 265.54M
Year | Enterprise Value | Change |
---|---|---|
2021 | 1.82B | -21.53% |
2020 | 2.32B | -47.49% |
2019 | 4.41B | 141.68% |
2018 | 1.82B | 24.35% |
2017 | 1.47B | 278.34% |
2016 | 387.77M | 46.03% |
2015 | 265.54M | -50.94% |
2014 | 541.20M | -42.21% |
The current Enterprise Value of Global Blood Therapeutics, Inc. (GBT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.85B
5-year avg
2.37B
10-year avg
1.55B
Global Blood Therapeutics, Inc.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Global Blood Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Global Blood Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Global Blood Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Global Blood Therapeutics, Inc. (GBT)?
What is the 3-year average Enterprise Value for Global Blood Therapeutics, Inc. (GBT)?
What is the 5-year average Enterprise Value for Global Blood Therapeutics, Inc. (GBT)?
How does the current Enterprise Value for Global Blood Therapeutics, Inc. (GBT) compare to its historical average?